To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.
Instead of expanding at its New Jersey headquarters, Legend Biotech opened its new R&D center in Philadelphia. This strategic move aims to attract specialized scientific talent by deliberately locating in a key innovation hub for cell therapy, demonstrating a "go to the talent" growth strategy.
A key driver of Legend Biotech's $2 billion revenue run rate is its successful regulatory strategy. By getting its CAR T therapy, CARVICTI, approved as a second-line treatment in both the US and Europe, the company significantly expanded its addressable patient market beyond last-resort cases.